-The Hindu The International Commission on Non-Ionizing Radiation Protection (ICNIRP) guidelines of April 1998 say epidemiological studies on workers exposed to Electric and Magnetic Field (EMF) and the public have shown no major health effects associated with typical exposure environments. The studies have yielded no convincing evidence that typical exposure levels lead to adverse reproductive outcomes or an increased Cancer risk. In India, the GSM services are being operated in 900 MHz and...

-The Hindu The government has issued a warning letter to Programme for Appropriate Technology in Health (PATH), asking it to be careful while conducting clinical trials so as to ensure that discrepancies and violations are not repeated in future. The Indian Council of Medical Research (ICMR) had suspended the Phase-V post licensure clinical trial being conducted by PATH, an international non-governmental organisation, in Khamman (Andhra Pradesh) and Vadodara (Gujarat) for Human Papilloma...

-Live Mint The Comptroller and Auditor General (CAG) has criticized India’s atomic energy regulator for not being truly independent, not having a radiation safety policy and being lax in monitoring the proliferation of unregistered medical X-ray facilities in the country. This is the first time ever that the performance of the 29-year-old Atomic Energy Regulatory Board (AERB) has been reviewed by the government’s auditor. The move follows criticism of the safety of...

-PTI Clinical drug trials in India led to the death of 1144 people in 2010 and 2011, the government today said. The number of people dying during such trials also include 1106 people whose death could be attributed to diseases like Cancer, terminal illness or various unrelated causes which is also known as Serious Adverse Event (SAE) of death, Health and Family Welfare Minister Ghulam Nabi Azad told the Rajya Sabha. "The number...

-The Economic Times Drug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last year, leading to sharp criticism about the paltry sums being handed out and growing clamour among health groups for more stringent guidelines on new drug trials.  According to government data accessed by a healthcare activist through an RTI query, Germany's Fresenius Kabi paid 50,000 each to the...